Edward Keystone

37.3k total citations · 13 hit papers
404 papers, 24.5k citations indexed

About

Edward Keystone is a scholar working on Rheumatology, Hematology and Genetics. According to data from OpenAlex, Edward Keystone has authored 404 papers receiving a total of 24.5k indexed citations (citations by other indexed papers that have themselves been cited), including 309 papers in Rheumatology, 139 papers in Hematology and 106 papers in Genetics. Recurrent topics in Edward Keystone's work include Rheumatoid Arthritis Research and Therapies (293 papers), Autoimmune and Inflammatory Disorders Research (127 papers) and Systemic Lupus Erythematosus Research (103 papers). Edward Keystone is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (293 papers), Autoimmune and Inflammatory Disorders Research (127 papers) and Systemic Lupus Erythematosus Research (103 papers). Edward Keystone collaborates with scholars based in Canada, United States and United Kingdom. Edward Keystone's co-authors include Paul Emery, Mark C. Genovese, Larry W. Moreland, Michael Schiff, Michael E. Weinblatt, Steven Fischkoff, Roy Fleischmann, Elliot Chartash, Joan M. Bathon and Désirée van der Heijde and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Edward Keystone

390 papers receiving 23.5k citations

Hit Papers

Adalimumab, a fully human... 2000 2026 2008 2017 2003 2000 2006 2004 2004 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial
    2003 1.4k citations Edward Keystone et al. Arthritis & Rheumatism profile →
  2. A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
    2000 1.4k citations Edward Keystone, Mark C. Genovese et al. profile →
  3. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
    2006 1.3k citations Mark C. Genovese, Edward Keystone et al. Arthritis & Rheumatism profile →
  4. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo‐controlled, 52‐week trial
    2004 956 citations Edward Keystone et al. Arthritis & Rheumatism profile →
  5. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
    2004 940 citations Josef S Smolen, Edward Keystone et al. Arthritis & Rheumatism profile →
  6. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    2008 866 citations Edward Keystone et al. Annals of the Rheumatic Diseases profile →
  7. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
    2017 621 citations Edward Keystone et al. profile →
  8. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
    2002 573 citations Mark C. Genovese, Edward Keystone et al. Arthritis & Rheumatism profile →
  9. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management
    2003 559 citations Edward Keystone et al. profile →
  10. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    2005 502 citations Arthur Kavanaugh, Gerd R Burmester et al. Arthritis & Rheumatism profile →
  11. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    2008 465 citations Edward Keystone et al. Arthritis & Rheumatism profile →
  12. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Edward Keystone, Peter Nash et al. Arthritis & Rheumatism profile →
  13. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study
    2008 432 citations Edward Keystone, Mark C. Genovese et al. Annals of the Rheumatic Diseases profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Edward Keystone 17.0k 7.8k 6.8k 4.2k 3.1k 404 24.5k
Roy Fleischmann 16.7k 1.0× 8.1k 1.0× 6.4k 0.9× 3.9k 0.9× 2.4k 0.8× 347 22.9k
Joel M. Kremer 15.2k 0.9× 6.9k 0.9× 5.0k 0.7× 4.1k 1.0× 2.3k 0.8× 322 23.2k
Mark C. Genovese 14.1k 0.8× 6.5k 0.8× 8.5k 1.3× 3.5k 0.8× 2.5k 0.8× 317 22.7k
Ronald van Vollenhoven 20.6k 1.2× 6.8k 0.9× 10.0k 1.5× 4.4k 1.1× 3.5k 1.1× 512 27.7k
Ferdinand C. Breedveld 15.2k 0.9× 5.4k 0.7× 5.4k 0.8× 2.6k 0.6× 2.0k 0.6× 182 21.9k
Ben A. C. Dijkmans 18.3k 1.1× 6.1k 0.8× 6.3k 0.9× 2.1k 0.5× 2.3k 0.7× 332 25.0k
Josef S Smolen 25.5k 1.5× 9.6k 1.2× 10.1k 1.5× 4.0k 0.9× 3.9k 1.3× 509 35.4k
Larry W. Moreland 12.2k 0.7× 5.0k 0.6× 4.7k 0.7× 2.4k 0.6× 2.3k 0.7× 291 18.9k
Vibeke Strand 15.4k 0.9× 5.6k 0.7× 6.3k 0.9× 2.0k 0.5× 2.6k 0.8× 522 22.9k
Michael H. Weisman 14.9k 0.9× 5.0k 0.6× 6.2k 0.9× 1.9k 0.5× 2.4k 0.8× 340 22.2k

Countries citing papers authored by Edward Keystone

Since Specialization
Citations

This map shows the geographic impact of Edward Keystone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Keystone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Keystone more than expected).

Fields of papers citing papers by Edward Keystone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward Keystone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Keystone. The network helps show where Edward Keystone may publish in the future.

Co-authorship network of co-authors of Edward Keystone

This figure shows the co-authorship network connecting the top 25 collaborators of Edward Keystone. A scholar is included among the top collaborators of Edward Keystone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward Keystone. Edward Keystone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Meng, Charis F., Yvonne Lee, Orit Schieir, et al.. (2024). Having More Tender Than Swollen Joints is Associated With Worse Function and Work Impairment in Patients With Early Rheumatoid Arthritis. ACR Open Rheumatology. 6(6). 347–355. 2 indexed citations
2.
3.
4.
Haranaka, Miwa, Takashi Eto, Takanori Tanaka, et al.. (2024). Pharmacokinetics and Safety of Intravenous Candidate Biosimilar CT‐P47 and Reference Tocilizumab: A Randomized, Double‐Blind, Phase 1 Study. The Journal of Clinical Pharmacology. 65(2). 233–241. 2 indexed citations
5.
Yu, Kyung‐Sang, Dongseong Shin, Min Kyu Park, et al.. (2024). Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study. Expert Opinion on Biological Therapy. 24(7). 681–689. 2 indexed citations
6.
Movahedi, Mohammad, D. Choquette, Louis Coupal, et al.. (2023). Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada. BMJ Open. 13(3). e063198–e063198. 4 indexed citations
7.
Andersen, Kathleen M., Orit Schieir, Marie‐France Valois, et al.. (2021). A Bridge Too Far? Real‐World Practice Patterns of Early Glucocorticoid Use in the Canadian Early Arthritis Cohort. ACR Open Rheumatology. 4(1). 57–64. 10 indexed citations
8.
Deardon, Rob, Cheryl Barnabé, Vivian P. Bykerk, et al.. (2019). Joint Estimation of Remission and Response for Methotrexate‐Based DMARD Options in Rheumatoid Arthritis: A Bivariate Network Meta‐Analysis. ACR Open Rheumatology. 1(8). 471–479. 4 indexed citations
9.
Moura, Cristiano Soares de, Orit Schieir, Marie‐France Valois, et al.. (2019). Treatment Strategies in Early Rheumatoid Arthritis Methotrexate Management: Results From a Prospective Cohort. Arthritis Care & Research. 72(8). 1104–1111. 12 indexed citations
10.
Barber, Claire, Orit Schieir, Diane Lacaille, et al.. (2018). High Adherence to System‐Level Performance Measures for Rheumatoid Arthritis in a National Early Arthritis Cohort Over Eight Years. Arthritis Care & Research. 70(6). 842–850. 13 indexed citations
11.
Nagaraj, Sujay, Cheryl Barnabé, Orit Schieir, et al.. (2017). Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis. Arthritis Care & Research. 70(8). 1245–1250. 19 indexed citations
12.
Pope, Janet, Carol Hitchon, Gilles Boire, et al.. (2016). The effect of rheumatoid arthritis–associated autoantibodies on the incidence of cardiovascular events in a large inception cohort of early inflammatory arthritis. Lara D. Veeken. 56(5). kew474–kew474. 23 indexed citations
13.
Fürst, Daniel E., Jonathan Kay, Mary Chester Wasko, et al.. (2013). The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Lara D. Veeken. 52(10). 1845–1855. 26 indexed citations
14.
Visser, K., Janet Pope, Susan J. Bartlett, et al.. (2013). Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis. Data Archiving and Networked Services (DANS). 65. 1 indexed citations
15.
Alten, Rieke, Jeffrey Kaine, Edward Keystone, et al.. (2012). Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure. Queensland's institutional digital repository (The University of Queensland). 3 indexed citations
16.
Xie, Gang, Yue Lu, Ye Sun, et al.. (2012). Identification of the NF-κB activating protein-like locus as a risk locus for rheumatoid arthritis. Annals of the Rheumatic Diseases. 72(7). 1249–1254. 8 indexed citations
17.
Landewé, R., Edward Keystone, Smolen Js, et al.. (2011). DISCONNECT BETWEEN DISEASE ACTIVITY AND JOINT SPACE NARROWING FOR PATIENTS WITH EARLY RA TREATED WITH ADALIMUMAB PLUS METHOTREXATE BUT NOT METHOTREXATE ALONE: CASE FOR ANTI-TNF CARTILAGE PROTECTION. Lara D. Veeken. 50. 113–113. 2 indexed citations
18.
Narendran, Aru, Hooman Ganjavi, Alison Connor, et al.. (2003). Mutant p53 in bone marrow stromal cells increases VEGF expression and supports leukemia cell growth. Experimental Hematology. 31(8). 693–701. 47 indexed citations
19.
Cava, Antonio La, J. Lee Nelson, William Ollier, et al.. (1997). Genetic bias in immune responses to a cassette shared by different microorganisms in patients with rheumatoid arthritis.. Journal of Clinical Investigation. 100(3). 658–663. 58 indexed citations
20.
Abel, Thomas, Murray B. Urowitz, H A Smythe, et al.. (1978). Proceedings of the 42nd annual meeting of the american rheumatism association a section of the arthritis foundation june 1 & 2, 1978 new york city abstracts of papers presented. Arthritis & Rheumatism. 21(5). 539–606. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roy Fleischmann Breakdown of academic impact, for papers by Joel M. Kremer Breakdown of academic impact, for papers by Mark C. Genovese Breakdown of academic impact, for papers by Ronald van Vollenhoven Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Josef S Smolen Breakdown of academic impact, for papers by Larry W. Moreland Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Michael H. Weisman
Rankless by CCL
2026